Ribosomal S6 Kinase (RSK)
S6K
Ribosomal S6 Kinase (RSK) is a family of serine/threonine protein kinases involved in the regulation of cell viability. RSK is phosphorylated in response to mitogens by activation of one or more protein kinase cascades. Phosphorylation of S6 in vivo is catalyzed by (at least) two distinct mitogen-activated S6 kinase families distinguishable by size, the 70 kDa and 90 kDa S6 kinases. Both S6 kinases are activated by serine/threonine phosphorylation.
The p90 ribosomal s6 kinase family (1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. They regulate diverse cellular processes, such as cell growth, cell motility, cell survival and cell proliferation. The p70 ribosomal protein S6 kinase, an important member of AGC family, is a kind of multifunctional Ser/Thr kinases, which plays an important role in mTOR signaling cascade. The p70 ribosomal protein S6 kinase is closely associated with diverse cellular processes such as protein synthesis, mRNA processing, glucose homeostasis, cell growth and apoptosis.
Ribosomal S6 Kinase (RSK) Isoform Specific Products
All Product Categories
-
Ribosomal S6 Kinase (RSK) Related Products (96)
Related Products (96)
-
Antibodies (9)
-
Ribosomal S6 Kinase (RSK) Isoform Comparison
-
Sapanisertib (Standard)
0 ImagesSynonyms: INK-128 (Standard); MLN0128 (Standard); TAK-228 (Standard)Sapanisertib (INK-128; MLN0128; TAK-228) Standard is the analytical standard of Sapanisertib (HY-13328). This product is intended for research and analytical applications. Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
-
M2698 (Standard)
0 ImagesSynonyms: MSC2363318A (Standard)M2698 (Standard) is the analytical standard of M2698 (HY-100501). This product is intended for research and analytical applications. M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.
-
RSK2-IN-4
0 ImagesCat. No.: HY-W286614CAS No.: 62001-32-5RSK2-IN-4 (Compound 10) is a RSK2 inhibitor, with an inhibition rate of 13.73% on RSK2 activity at 10 μM. RSK2-IN-4 binds to the ATP-binding site of RSK2 in the NTKD (N-terminal kinase domain), with the electron-donating group at the 4-position of the phenyl ring being the key determinant for its inhibitory activity .
-
(E/Z)-PV1162
0 ImagesCat. No.: HY-164523ACAS No.: 1346559-65-6
-
SB-699551 (Standard)
0 ImagesCat. No.: HY-103100RCAS No.: 864741-95-7SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a Ki value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.
-
CInQ-03
0 ImagesCat. No.: HY-130453CAS No.: 500272-80-0CInQ-03 is an allosteric inhibitor of MEK1/2, with IC50 values of 5 μM and 10 μM against MEK1 and MEK2, respectively. CInQ-03 inhibits the kinase activity of MEK1/2 and reduces the phosphorylation levels of downstream ERK1/2 and RSK. CInQ-03 suppresses both anchorage-dependent and anchorage-independent growth of colon cancer cells, the activity of AP-1 reporter gene in colon cancer cells, as well as EGF-induced growth, transformation and AP-1 reporter gene activity in HaCaT keratinocytes. CInQ-03 can be used in studies related to colon cancer.
-
RMC-7977 (Standard)
0 ImagesCat. No.: HY-156498RCAS No.: 2765082-12-8RMC-7977 (Standard) is the analytical standard of RMC-7977 (HY-156498). This product is intended for research and analytical applications. RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models.
-
Sodium Salicylate (Standard)
0 ImagesSynonyms: Salicylic acid sodium salt (Standard); 2-Hydroxybenzoic acid sodium salt (Standard)Sodium Salicylate (Standard) is the analytical standard of Sodium Salicylate. This product is intended for research and analytical applications. Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.
-
Pluripotin (Standard)
0 ImagesCat. No.: HY-10579RCAS No.: 839707-37-8Synonyms: SC1 (Standard)Pluripotin (Standard) is the analytical standard of Pluripotin (HY-10579). This product is intended for research and analytical applications. Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 μM, respectively.
-
BI-D1870 (Standard)
0 ImagesBI-D1870 (Standard) is the analytical standard of BI-D1870 (HY-10510). This product is intended for research and analytical applications. BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC50s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively.
-
VJ115
0 ImagesCat. No.: HY-111089CAS No.: 929256-79-1VJ115 is a potent ENOX1 inhibitor with an EC50 of 50 μM. By inhibiting ENOX1, VJ115 elevates NADH, which in turn downregulates the phosphorylation of p70S6K1/S6, alters the expression of c-Jun and cytoskeletal proteins, induces endothelial cells to lose polarization and migration ability, and increases caspase-3-dependent apoptosis under radiation. VJ115 can be used in studies related to solid tumors.
-
LY-2584702 hydrochloride
0 ImagesCat. No.: HY-12493BCAS No.: 1082948-81-9LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
-
Sapanisertib phosphate
0 ImagesCat. No.: HY-13328ACAS No.: 1422006-47-0Synonyms: INK-128 phosphate; MLN0128 phosphate; TAK-228 phosphateSapanisertib (INK-128; MLN0128; TAK-228) phosphate is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib phosphate directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib phosphate is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies.
